Assessment of genetic and non-genetic risk factors for venous thromboembolism in glioblastoma – The predictive significance of B blood group

Heenkenda, Menikae Kanchena; Malmström, Annika; Łysiak, M; Mudaisi, Munila; Bratthäll, Charlotte; Milos, Peter; Strandéus, Michael; Åkesson, Lisa; Söderkvist, Peter; Uppugunduri, Srinivas; Osman, Abdimajid

doi:10.1016/j.thromres.2019.10.009

Cited by 13 publications

(14 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From these, we removed 40 duplicates and excluded non-relevant studies, review articles, meeting abstracts, case reports, replies, editorials or commentaries, and studies in languages other than English. This left 40 studies for review, from which we identified nine studies for systematic review [13][14][15][16][17][18][19][20][21] and five studies [14,15,[17][18][19] for qualitative meta-analysis (Figure 1). cluded in the meta-analysis.…”

Section: Study Selectionmentioning

confidence: 99%

“…In addition, the timing of diagnostic evaluation of patients for venous thromboembolism was based on symptom presentation and/or clinical evaluation, and most of the studies did not follow a precise protocol. Multivariate logistic regression analyses were not performed in three studies [13,16,20], and although Wang et al evaluated the association of venous thromboembolism with ABO blood type, they reported a higher risk of each non-O blood type (A/B/AB) compared to O blood type (OR (95% CI); A: 2.072 (1.204-3.566), B: 1.944 (1.020-3.873), AB: 2.706 (1.432-5.114)). These four studies were excluded from our meta-analysis.…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

See 1 more Smart Citation

The Impact of ABO Blood Type on Developing Venous Thromboembolism in Cancer Patients: Systematic Review and Meta-Analysis

Urabe

Kimura

Iwatani

et al. 2021

JCM

View full text Add to dashboard Cite

The impact of ABO blood type in the development of venous thromboembolism in cancer patients remains controversial. To develop a sense of the current opinion in this area, we conducted a systematic review and meta-analysis. In March 2021, we performed a systematic search of PubMed, the Cochrane library, and Scopus for studies that compared cancer patients who had a blood type of either O or non-O (A, B, and AB). Our objective was to use multivariate logistic regression analysis to determine how ABO blood type was associated with the development of venous thromboembolism. Our selection criteria were met by a total of nine studies in 25,884 patients for the systematic review and five studies in 22,777 patients for the meta-analysis. In cancer patients, we found that non-O blood type was associated with a nearly two-fold increase in risk of venous thromboembolism (pooled OR: 1.74, 95% CI: 1.44–2.10). Additionally, among the eligible patients, 21,889 patients were post-operative urological cancer patients. In these patients, the analysis also showed an association between non-O blood type and increasing risk of venous thromboembolism after pelvic surgery for malignancy (pooled OR: 1.73, 95% CI: 1.36–2.20). Our meta-analysis suggested that non-O blood type is a risk factor for venous thromboembolism among patients with cancer. As blood type is routinely determined preoperatively by objective and standardized methods, we anticipate that our results will be useful for managing venous thromboembolism in cancer patients, especially after pelvic surgery for urological cancers.

show abstract

Section: Study Selectionmentioning

confidence: 99%

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

The Impact of ABO Blood Type on Developing Venous Thromboembolism in Cancer Patients: Systematic Review and Meta-Analysis

Urabe

Kimura

Iwatani

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“… 97 Similarly, the odds of VTE in those with glioblastoma, pancreatic cancer, and prostate cancer were increased in those with a non-O vs O blood type, similar to the ABO effect in the cancer-free population. 98 , 99 , 100 …”

Section: Vwf In Special Cases Of Vte Diseasementioning

confidence: 99%

Role of von Willebrand factor in venous thromboembolic disease

Michels

Lillicrap

Yacob

2022

JVS-Vascular Science

View full text Add to dashboard Cite

Objective Evolving evidence of the shared risk factors and pathogenic mechanisms in arterial and venous thrombosis questions of the strict vascular dichotomy of arterial vs venous. The connection between arterial and venous thrombosis has been highlighted by common underlying inflammatory processes, a concept known as thromboinflammatory disease. Using this relationship, we can apply knowledge from arterial disease to better understand and potentially mitigate venous disease. A protein that has been extensively studied in atherothrombotic disease and inflammation is von Willebrand factor (VWF). Because many predisposing and provoking factors of venous thromboembolism (VTE) have been shown to directly modulate VWF levels, it is, perhaps, not surprising that VWF has been highlighted by several recent association studies of patients with VTE. Methods In the present narrative review, we investigated more deeply the effects of VWF in venous disease by synthesizing the data from clinical studies of deep vein thrombosis of the limbs, pulmonary embolism, portal and cerebral vein thrombosis, and the complications of thrombosis, including post-thrombotic syndrome, venous insufficiency, and chronic thromboembolic pulmonary hypertension. We have also discussed the findings from preclinical studies to highlight novel VWF biochemistry in thrombosis and therapeutics. Results Across the spectrum of venous thromboembolic disease, we consistently observed that elevated VWF levels conferred an increased risk of VTE and long-term venous complications. We have highlighted important findings from VWF molecular research and have proposed mechanisms by which VWF participates in venous disease. Emerging evidence from preclinical studies might reveal novel targets for thromboinflammatory disease, including specific VWF pathophysiology. Furthermore, we have highlighted the utility of measuring VWF to prognosticate and risk stratify for VTE and its complications. Conclusions As the prevalence of inflammatory processes, such as aging, obesity, and diabetes increases in our population, it is critical to understand the evolving role of VWF in venous disease to guide clinical decisions and therapeutics.

show abstract

“…The association of blood group with VTEs in glioma patients has been discussed controversially. Whereas B blood group was found to be predictive for VTEs in a cohort of 139 glioblastoma patients [13], this was not confirmed in a prospective study of patients diagnosed with glioma, including glioblastoma [7]. Elevated factor VIII levels [7] and low platelets or high leukocytes [14] have been reported to increase the risk of VTEs in glioblastoma patients.…”

Section: Introductionmentioning

confidence: 99%

Venous thromboembolic events in glioblastoma patients: An epidemiological study

Eisele

Seystahl

Roth

et al. 2022

Euro J of Neurology

View full text Add to dashboard Cite

Background and purpose Venous thromboembolic events (VTEs) are a major complication in cancer patients, and therefore, also in brain cancer patients, anticoagulants are considered appropriate in the treatment of VTEs. Methods Frequency, risk factors, and treatment of VTEs, as well as associated complications, were assessed in a population‐based cohort of glioblastoma patients in the Canton of Zurich, Switzerland. Correlations between clinical data and survival were retrospectively analyzed using the log‐rank test and Cox regression models. Results Four hundred fourteen glioblastoma patients with isocitrate dehydrogenase wild‐type status were identified. VTEs were documented in 65 patients (15.7%). Median time from tumor diagnosis to the occurrence of a VTE was 1.8 months, and 27 patients were diagnosed with VTEs postoperatively (within 35 days; 42.2%). History of a prior VTE was more common in patients who developed VTEs than in those who did not (p = 0.004). Bevacizumab treatment at any time during the disease course was not associated with occurrence of VTEs (p = 0.593). Most patients with VTEs (n = 61, 93.8%) were treated with therapeutic anticoagulation. Complications occurred in 14 patients (23.0%), mainly intracranial hemorrhages (n = 7, 11.5%). Overall survival did not differ between patients diagnosed with VTEs and those who had no VTE (p = 0.139). Tumor progression was the major cause of death (n = 283, 90.7%), and only three patients (1.0%) died in association with acute VTEs. Conclusions Venous thromboembolic events occurred early in the disease course, suggesting that the implementation of primary venous thromboembolism prophylaxis during first‐line chemoradiotherapy could be explored in a randomized setting.

show abstract

Assessment of genetic and non-genetic risk factors for venous thromboembolism in glioblastoma – The predictive significance of B blood group

Cited by 13 publications

References 44 publications

The Impact of ABO Blood Type on Developing Venous Thromboembolism in Cancer Patients: Systematic Review and Meta-Analysis

The Impact of ABO Blood Type on Developing Venous Thromboembolism in Cancer Patients: Systematic Review and Meta-Analysis

Role of von Willebrand factor in venous thromboembolic disease

Venous thromboembolic events in glioblastoma patients: An epidemiological study

Contact Info

Product

Resources

About